- Conditions
- Myasthenic Syndromes, Congenital
- Interventions
- amifampridine phosphate, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
- Interventions
- Continuous 3,4-DAP, Taper 3,4-DAP to Placebo
- Drug
- Lead sponsor
- Jacobus Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 7
- States / cities
- Sacramento, California • Indianapolis, Indiana • Durham, North Carolina + 4 more
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- Amifampridine Phosphate, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 3 more
- Conditions
- Muscle Weakness
- Interventions
- 3-4 Diaminopyridine
- Drug
- Lead sponsor
- Jeffrey A. Cohen, MD
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
- Interventions
- Amifampridine Phosphate
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Total Knee Arthroplasty, Rehabilitation
- Interventions
- Anti-gravity treadmill, PENS - neuro-muscular stimulation, Anti-gravity treadmill & PENS - neuro-muscular stimulation, Recumbent or Nu-step bike
- Other
- Lead sponsor
- MedStar National Rehabilitation Network
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- 3, 4-Diaminopyridine
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lambert Eaton Myasthenic Syndrome (LEMS)
- Interventions
- 3,4-diaminopyridine
- Drug
- Lead sponsor
- Louis H. Weimer, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lambert-Eaton Myasthenic Syndrome
- Interventions
- Amifampridine Phosphate, Placebo Oral Tablet
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- 3, 4 DAP
- Drug
- Lead sponsor
- David P. Richman, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Amifampridine Phosphate, Placebo Oral Tablet
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Obesity
- Interventions
- Pramlintide (Amylin), Placebo (Normal Saline), 2 Metreleptin, Leptin plus Pramlintide
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
- Interventions
- Amifampridine Phosphate
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Botulism, Iatrogenic Botulism
- Interventions
- Amifampridine
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina